Please wait while the formulary information is being retrieved.
ESTRADIOL (estradiol)
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Primary ovarian failure
- Vasomotor symptoms associated with menopause
- Advanced prostatic carcinoma
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Female hypogonadism
- Hypoestrogenism due to bilateral oophorectomy
- Metastatic breast carcinoma
- Metastatic prostate carcinoma
- Post-menopausal osteoporosis prevention
- Primary ovarian failure
- Yuvafem Vaginal Tablet
- Vivelle-dot Transdermal Patch
- Vagifem Vaginal Tablet
- Minivelle Transdermal Patch
- Estradiol Weekly Transdermal Patch
- Estradiol Vaginal Tablet
- Estradiol Vaginal Cream
- Estradiol Tablet
- Estradiol Semiweekly Transdermal Patch
- Estrace Vaginal Cream
- Estrace Tablet
- Dotti Transdermal Patch
- Climara Transdermal Patch
- Alora Transdermal Patch
- Alora Transderm Patch
- By Indication
10 mcg vaginal tablet
- Insert 1 tablet (10 mcg) by vaginal route once daily for 14 days then1 tablet (10 mcg) 2 times per week for duration of use
0.025 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.0375 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.05 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.075 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.1 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
10 mcg vaginal tablet
- Insert 1 tablet (10 mcg) by vaginal route once daily for 14 days then1 tablet (10 mcg) 2 times per week for duration of use
0.025 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.0375 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.05 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.075 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.1 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.025 mg/24 hr weekly transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.0375 mg/24 hr weekly transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.05 mg/24 hr weekly transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.06 mg/24 hr weekly transdermal patch
- Apply 1 patch by transdermal route once weekly
0.075 mg/24 hr weekly transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.1 mg/24 hr weekly transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
14 mcg/24 hr weekly transdermal patch
- Apply 1 patch to the lower abdomen area by transdermal route every 7 days
10 mcg vaginal tablet
- Insert 1 tablet (10 mcg) by vaginal route once daily for 14 days then1 tablet (10 mcg) 2 times per week for duration of use
0.01% (0.1 mg/gram) vaginal cream
- Insert 1 gram by vaginal route once weekly
0.5 mg tablet
- 1 tablet (0.5 mg) by oral route once daily days 1-21
1 mg tablet
- 1 tablet (1 mg) by oral route once daily
2 mg tablet
- 1 tablet (2 mg) by oral route once daily
0.025 mg/24 hr semiweekly transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.0375 mg/24 hr semiweekly transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.05 mg/24 hr semiweekly transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.075 mg/24 hr semiweekly transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.1 mg/24 hr semiweekly transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.01% (0.1 mg/gram) vaginal cream
- Insert 1 gram by vaginal route once weekly
0.5 mg tablet
- 1 tablet (0.5 mg) by oral route once daily days 1-21
1 mg tablet
- 1 tablet (1 mg) by oral route once daily
2 mg tablet
- 1 tablet (2 mg) by oral route once daily
Estrace 0.5 mg tablet
- 1 tablet (0.5 mg) by oral route once daily days 1-21
Estrace 1 mg tablet
- 1 tablet (1 mg) by oral route once daily
Estrace 2 mg tablet
- 1 tablet (2 mg) by oral route once daily
0.025 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.0375 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.05 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.075 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.1 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.025 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.0375 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.05 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.06 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route once weekly
0.075 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.1 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
0.025 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.05 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.075 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.1 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.025 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.05 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
0.075 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
0.1 mg/24 hr transdermal patch
- Apply 1 patch by transdermal route twice weekly
Atrophic vaginitis associated with menopause
- 1 tablet (0.5 mg) by oral route once daily for 21 days off for 7Days; repeat cycle
- 1 tablet (0.5 mg) by oral route once daily
- 1 tablet (0.5 mg) by oral route once daily days 1-21
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
- Insert 1 gram by vaginal route once weekly
- Insert 1 gram by vaginal route 3 times per week
- Apply 1 patch by transdermal route once weekly
- Apply 1 patch by transdermal route twice weekly
- 1 tablet (1 mg) by oral route once daily days 1-21
- 2 tablets (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily days 1-21
- 1 tablet (1 mg) by oral route once daily
- 1 tablet (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily days 1-21
- 2 tablets (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily days 1-21
- 1 tablet (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- Insert 1 tablet (10 mcg) by vaginal route once daily for 14 days then1 tablet (10 mcg) 2 times per week for duration of use
- Insert 1 tablet (10 mcg) by vaginal route twice weekly
Atrophy of vulva
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
- Apply 1 patch by transdermal route once weekly
- Apply 1 patch by transdermal route twice weekly
- 1 tablet (1 mg) by oral route once daily
- 2 tablets (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily
- Insert 1 tablet (10 mcg) by vaginal route once daily for 14 days then1 tablet (10 mcg) 2 times per week for duration of use
- Insert 1 tablet (10 mcg) by vaginal route twice weekly
Female hypogonadism
- 1 tablet (0.5 mg) by oral route once daily for 21 days off for 7Days; repeat cycle
- 1 tablet (0.5 mg) by oral route once daily
- 1 tablet (0.5 mg) by oral route once daily days 1-21
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
- Apply 1 patch by transdermal route once weekly
- Apply 1 patch by transdermal route twice weekly
- 1 tablet (1 mg) by oral route once daily days 1-21
- 2 tablets (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily days 1-21
- 1 tablet (1 mg) by oral route once daily
- 1 tablet (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily days 1-21
- 2 tablets (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily days 1-21
- 1 tablet (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
Hypoestrogenism due to bilateral oophorectomy
- 1 tablet (0.5 mg) by oral route once daily
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
- Apply 1 patch by transdermal route once weekly
- Apply 1 patch by transdermal route twice weekly
- 1 tablet (1 mg) by oral route once daily
- 2 tablets (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily
Metastatic breast carcinoma
- 10 tablets (10 mg) by oral route 3 times per day
- 5 tablets (10 mg) by oral route 3 times per day
Post-menopausal osteoporosis prevention
- 1 tablet (0.5 mg) by oral route once daily for 21 days off for 7Days; repeat cycle
- 1 tablet (0.5 mg) by oral route once daily for 23 days off for 5Days, repeat cycle
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
- Apply 1 patch by transdermal route twice weekly
Postmenopausal urethral atrophy
- Insert 1 gram by vaginal route once weekly
- Insert 1 gram by vaginal route 3 times per week
- 1 tablet (1 mg) by oral route once daily
- 2 tablets (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily
- Insert 1 tablet (10 mcg) by vaginal route once daily for 14 days then1 tablet (10 mcg) 2 times per week for duration of use
- Insert 1 tablet (10 mcg) by vaginal route twice weekly
Pre-menopausal osteoporosis
- 1 tablet (0.5 mg) by oral route once daily for 21 days off for 7Days; repeat cycle
- 1 tablet (0.5 mg) by oral route once daily for 23 days off for 5Days, repeat cycle
Primary ovarian failure
- 1 tablet (0.5 mg) by oral route once daily for 21 days off for 7Days; repeat cycle
- 1 tablet (0.5 mg) by oral route once daily
- 1 tablet (0.5 mg) by oral route once daily days 1-21
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
- Apply 1 patch by transdermal route once weekly
- Apply 1 patch by transdermal route twice weekly
- 1 tablet (1 mg) by oral route once daily days 1-21
- 2 tablets (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily days 1-21
- 1 tablet (1 mg) by oral route once daily
- 1 tablet (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily days 1-21
- 2 tablets (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily days 1-21
- 1 tablet (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
Vasomotor symptoms associated with menopause
- 1 tablet (0.5 mg) by oral route once daily for 21 days off for 7Days; repeat cycle
- 1 tablet (0.5 mg) by oral route once daily
- 1 tablet (0.5 mg) by oral route once daily days 1-21
- Apply 1 patch by transdermal route once weekly cyclically, 3 weeks onand 1 week off
- Apply 1 patch by transdermal route twice weekly cyclically, 3 weeks on and 1 week off
- Apply 1 patch by transdermal route once weekly
- Apply 1 patch by transdermal route twice weekly
- 1 tablet (1 mg) by oral route once daily days 1-21
- 2 tablets (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily days 1-21
- 1 tablet (1 mg) by oral route once daily
- 1 tablet (1 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (1 mg) by oral route once daily
- 2 tablets (2 mg) by oral route once daily days 1-21
- 2 tablets (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- 2 tablets (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily days 1-21
- 1 tablet (2 mg) by oral route once daily
- 1 tablet (2 mg) by oral route once daily for 21 days off for 7 days; repeat cycle
- anastrozole
- Arimidex
- Aromasin
- Cyklokapron
- exemestane
- Femara
- letrozole
- Lysteda
- tranexamic acid
Contraindicated
- None
Severe
Moderate
- A-hydrocort
- A-methapred
- Alagesic Lq
- amobarbital
- Amytal
- Anucort-hc
- Anusol-hc
- Aristospan Intra-articular
- Aristospan Intralesional
- Ascomp With Codeine
- Belladonna-phenobarbital
- betamethasone acet & sod phos
- Bivigam
- Brevital
- budesonide
- Bupap
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- Carimune Nf Nanofiltered
- Celestone Soluspan
- Cerebyx
- codeine-butalbital-ASA-caff
- Colocort
- Cortef
- Cortenema
- Cortifoam
- cortisone
- Depo-medrol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Entocort Ec
- Esgic
- ethotoin
- Evista
- Ez Use Joint-tunnel-trigger
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- First-duke's
- First-mary's Mouthwash
- Flebogamma Dif
- Flo-pred
- fludrocortisone
- fosphenytoin
- Gamastan S/d
- Gammagard Liquid
- Gammagard S-d (iga < 1 Mcg/ml)
- Gammagard S/d
- Gammaked
- Gammaplex
- Gamunex-c
- Grx Hicort 25
- Hemril-30
- Hizentra
- hydrocortisone
- hydrocortisone acetate
- hydrocortisone sod succ (PF)
- hydrocortisone sod succinate
- immune glob(IgG)(hum)-maltose
- immune globulin (human) (IgG)
- immune globulin(hum),capr(IgG)
- Kenalog
- Luminal
- Margesic
- Marten-tab
- Medrol
- Medrol (pak)
- methohexital
- methylprednisolone
- methylprednisolone acetate
- methylprednisolone sod suc(PF)
- methylprednisolone sodium succ
- methylprednisolone-bupivacaine
- Millipred
- Millipred Dp
- Mysoline
- Nembutal Sodium
- nystatin-hydrocortisone-diphen
- nystatin-TCN-HC-diphenhydramin
- Octagam
- Orapred
- Orapred Odt
- Pediapred
- Peganone
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Physicians Ez Use M-pred
- prednisolone
- prednisolone acetate
- prednisolone sodium phosphate
- prednisone
- Prednisone Intensol
- primidone
- Privigen
- Proctocort
- raloxifene
- Rayos
- Rectacort-hc
- secobarbital sodium
- Seconal Sodium
- Solu-cortef
- Solu-cortef (pf)
- Solu-medrol
- Solu-medrol (pf)
- Tencon
- triamcinolone acetonide
- triamcinolone hexacetonide
- triamcinolone-lidocaine
- Uceris
- Veripred 20
- Zebutal
- Abnormal uterine bleeding
- Acute myocardial infarction
- Antithrombin III deficiency
- Carcinoma of breast
- Cerebrovascular accident
- Deep venous thrombosis
- Disease of liver
- Estrogen-dependent neoplasm
- Predisposition to thrombosis
- Protein C deficiency disease
- Pulmonary thromboembolism
- Thromboembolic disorder
- Thrombophilia
- Thrombotic disorder
Contraindicated
- Bed-ridden
- Carcinoma of breast
- Coronary artery disease
- Dementia
- Endometrial carcinoma
- Estrogen-dependent neoplasm
- Family history of malignant tumor of breast
- Hepatic porphyria
- Hereditary angioedema
- Hypercalcemia
- Increased cardiovascular event risk
- Invasive surgical procedure
- Malignant neoplasm of the ovary
- Mammography abnormal
- Migraine
- Neoplasm of female genital organ
- Papilledema
- Retinal thrombosis
- Tobacco smoker
- Valvular heart disease
Severe
Moderate
- Asthma
- Diabetes mellitus
- Edema
- Endometriosis
- Family history of malignant tumor of breast
- Gallbladder disease
- Hepatic porphyria
- Hypercholesterolemia
- Hypertension
- Hypertriglyceridemia
- Hypoparathyroidism
- Hypothyroidism
- Mammography abnormal
- Migraine
- Seizure disorder
- Systemic lupus erythematosus
- Tobacco smoker
- Unspecified lump in breast
- Uterine leiomyoma
ESTRADIOL (estradiol)
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Primary ovarian failure
- Vasomotor symptoms associated with menopause
- Advanced prostatic carcinoma
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Female hypogonadism
- Hypoestrogenism due to bilateral oophorectomy
- Metastatic breast carcinoma
- Metastatic prostate carcinoma
- Post-menopausal osteoporosis prevention
- Primary ovarian failure
- Abnormal vaginal bleeding
- Mastalgia
- Peripheral edema
- Weight gain
- Abdominal distension
- Abdominal pain with cramps
- Anorexia
- Back pain
- Breast milk flow decreased
- Dysmenorrhea
- Erythema
- Gynecomastia
- Headache disorder
- Infection
- Mastalgia
- Nausea
- Peripheral edema
- Pharyngitis
- Pruritus of skin
- Sinusitis
- Vulvovaginal candidiasis
- Weight gain
More Frequent
Severe
Less Severe
- Endometrial hyperplasia
- Gastroenteritis
- Upper respiratory infection
- Acne vulgaris
- Back pain
- Bronchitis
- Candidiasis
- Cervical discharge
- Constipation
- Cramps
- Diarrhea
- Dizziness
- General weakness
- Gynecomastia
- Headache disorder
- Libido changes
- Migraine
- Mood changes
- Nausea
- Neck pain
- Pelvic pain
- Pruritus of skin
- Skin irritation
- Vaginal discharge
- Vaginitis
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Acute pancreatitis
- Amenorrhea
- Anaphylaxis
- Angina
- Angioedema
- Cerebrovascular accident
- Change in corneal curvature
- Chorea
- Deep venous thrombosis
- Dementia
- Endometrial carcinoma
- Endometrial hyperplasia
- Erythema multiforme
- Erythema nodosum
- Fibrocystic breast disease
- Gallbladder obstruction
- Hepatitis
- Hypercalcemia
- Hypersensitivity drug reaction
- Hypertension
- Hypertriglyceridemia
- Hypocalcemia
- Influenza
- Involuntary muscle movement
- Malignant epithelial tumor of ovary
- Malignant neoplasm of the ovary
- Menorrhagia
- Neoplasm of breast
- Nipple discharge
- Obstructive hyperbilirubinemia
- Pharyngeal edema
- Precocious puberty
- Pulmonary thromboembolism
- Purpura
- Retinal thrombosis
- Skin rash
- Thromboembolic disorder
- Thrombotic disorder
- Unspecified lump in breast
- Urticaria
- Uterine leiomyoma
Less Severe
- Abdominal pain with cramps
- Abnormal vaginal bleeding
- Alopecia
- Amenorrhea
- Arthralgias
- Back pain
- Body fluid retention
- Chest pain
- Chloasma
- Cramps in legs
- Depression
- Diarrhea
- Dry skin
- Dysmenorrhea
- Dyspepsia
- Dyspnea
- Fallopian tube disorder
- Fatigue
- Flu-like symptoms
- Galactorrhea not associated with childbirth
- Genital organ pruritus
- Gynecomastia
- Hirsutism
- Hypertension
- Insomnia
- Irritability
- Malaise
- Menorrhagia
- Mood changes
- Muscle spasm
- Nervousness
- Nipple discharge
- Oral hypoesthesia
- Palpitations
- Paresthesia
- Pelvic pain
- Skin pigmentation enhancement
- Tongue swelling
- Upper respiratory infection
- Urticaria
- Uterine cramps
- Uterine leiomyoma
- Vaginal discharge
- Vaginal irritation
- Varicose veins
- Vertigo
- Vulvovaginal candidiasis
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Estradiol
May cause premature epiphyseal closure. Prepubertal use may induce vaginal bleeding, premature breast development.
Not indicated in pediatrics.
- 1 Day – 18 Years
- May cause premature epiphyseal closure. Prepubertal use may induce vaginal bleeding, premature breast development.
Estrogens, Vaginal
May cause premature epiphyseal closure. Prepubertal use may induce vaginal bleeding, premature breast development.
Not indicated in pediatrics.
- 1 Day – 18 Years
- Not indicated in pediatrics.
Estradiol
- Severity Level:
2
- Additional Notes: Not indicated during pregnancy; no known dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Estradiol
Limited data indicate higher excretion may occur w/vaginal vs transderm admin
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data indicate higher excretion may occur w/vaginal vs transderm admin |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Estrogenic Agents (systemic)
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Low-dose intravaginal estrogen may be used for management of vaginal symptoms (e.g. dyspareunia, recurrent UTIs). Cardiovascular-Avoid with active or history of DVT,PE or thromboembolic disease.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Estrogenic Agents (vaginal)
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Low-dose intravaginal estrogen may be used for management of vaginal symptoms (e.g. dyspareunia, recurrent UTIs). Cardiovascular-Avoid with active or history of DVT,PE or thromboembolic disease.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Estrogens, either used alone or with another hormone (progestin), have rarely caused very serious side effects. Discuss the risks and benefits of hormone treatment with your doctor. Estrogens should not be used to prevent heart disease or dementia.<br /><br /> Estrogens can increase the risk of cancer of the uterus (endometrial cancer). Taking a progestin as directed by your doctor can help decrease this risk. Tell your doctor right away if you have any unusual vaginal bleeding.<br /><br /> In postmenopausal women, estrogens can increase the risk of cancer of the ovaries, stroke, dementia, and serious blood clots in the legs. Estrogens alone do not appear to increase the risk of breast cancer when used for up to 7 years. Estrogen, when used with a progestin, can increase the risk of heart disease (such as heart attacks), stroke, serious blood clots in the lungs/legs, dementia, and cancer of the breast/ovaries.<br /><br /> The risk for serious side effects may depend on the dose of estrogen and the length of time it is used. Therefore, this medication should be used at the lowest effective dose and for the shortest amount of time. Discuss the use of this medication with your doctor and check with him/her regularly (for example, every 3 to 6 months) to see if you still need to use this medication.<br /><br />If you will be using this medication long-term, you should have regular complete physical exams (for example, once a year) as directed by your doctor. See also Notes section.
| Advanced prostatic carcinoma | |
| C61 | Malignant neoplasm of prostate |
| Atrophic vaginitis associated with menopause | |
| N95.2 | Postmenopausal atrophic vaginitis |
| Atrophy of vulva | |
| N90.5 | Atrophy of vulva |
| Female hypogonadism | |
| E28.39 | Other primary ovarian failure |
| Hypoestrogenism due to bilateral oophorectomy | |
| E89.4 | Postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| Metastatic breast carcinoma | |
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| Metastatic prostate carcinoma | |
| C61 | Malignant neoplasm of prostate |
| Post-menopausal osteoporosis prevention | |
| Z78.0 | Asymptomatic menopausal state |
| Primary ovarian failure | |
| E28.3 | Primary ovarian failure |
| E28.31 | Premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| Vasomotor symptoms associated with menopause | |
| N95.1 | Menopausal and female climacteric states |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
| 0-9 | A-Z |
|---|---|
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| C61 | Malignant neoplasm of prostate |
| C61 | Malignant neoplasm of prostate |
| E28.3 | Primary ovarian failure |
| E28.31 | Premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| E28.39 | Other primary ovarian failure |
| E89.4 | Postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| N90.5 | Atrophy of vulva |
| N95.1 | Menopausal and female climacteric states |
| N95.2 | Postmenopausal atrophic vaginitis |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
| Z78.0 | Asymptomatic menopausal state |
Formulary Reference Tool